All In Biotech

Drug Trial Radar · NCT05442047

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Efficacy and Safety of NNC6019-0001 at Two Dose Levels in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Aug 2, 2022

Primary completion

Feb 17, 2025

Study completion May 13, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jul 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study will look at if this medicine can reduce the symptoms of a heart disease due to TTR amyloidosis, such as heart failure. Participants will either get NNC6019-0001 (apotential new medicine) or placebo (a medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting NNC6019-0001 is two times higher than getting placebo. NNC6019-0001 is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe yet. Participants will get an infusion of the study medicine 13 times, once every 4 weeks. The study will last for about 64 weeks after the first dose of medicine. Participants cannot participate in this study if they have a heart disease other than a heart disease due to TTR amyloidosis.

Conditions

  • Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Interventions

  • NNC6019-0001Drug

    Participants will receive i.v infusionof NNC6019-0001.

  • Placebo (NNC6019-0001)Drug

    Participants will receive i.v. infusion of placebo (NNC6019-0001).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in 6-minute walk test (6-MWT)Time frame: From baseline (week 0) to visit 15 (week 52)
  2. Change in N-terminal-pro brain natriuretic peptide (NT-proBNP)Time frame: From baseline (week 0) to visit 15 (week 52)

Locations

39 sites in 10 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Cedars-Sinai Medical Center_Los Angeles

    Beverly Hills, California

  • Stanford Hlth Cre-Boswell Clin

    Stanford, California

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • NW Univ-Bluhm Cardiovasc Inst

    Evanston, Illinois

  • Univ of MD Schl of Med

    Baltimore, Maryland

  • University of Maryland School of Medicine

    Baltimore, Maryland

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Oregon Hlth Sci Univ-Portland

    Portland, Oregon

  • University of Calgary_Cardiology

    Calgary, Alberta, Canada

  • Ctr for Cardiovascular Innovation

    Vancouver, British Columbia, Canada

  • II. interni klinika VFN - Kardiologie a angiologie

    Prague, Czechia

  • Ap-Hp-Hopital Henri Mondor

    Créteil, France

  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil

    Toulouse, France

  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1

    Toulouse Cedex 9 TSA 50032, France

  • UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie

    Heidelberg, Germany

  • LMU Klinikum München Klinik und Poliklinik 1

    München, Germany

  • Universitätsklinikum Münster - Klinik für Kardiologie I

    Münster, Germany

  • Universitatsklinikum Wurzburg AöR

    Würzburg, Germany

  • Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz

    Würzburg, Germany

  • Fondazione Toscana Gabriele Monasterio - Dipartimento Cardiotoracico - UOC Cardiologia e Medicina Cardiovascolare

    Pisa, Pi, Italy

  • Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo

    Pavia, PV, Italy

  • Hospital of the University of Occupational and Environmental Health, Cardiology, Nephrology

    Fukuoka, Japan

  • Hospital of the University of Occupational and Environmental Health

    Fukuoka, Japan

  • Hiroshima University hospital, Cardiovascular Medicine

    Hiroshima, Japan

  • Hiroshima University hospital_Cardiovascular Medicine

    Hiroshima, Japan

  • Kumamoto University Hospital, Cardiovascular Medicine

    Kumamoto-shi, Kumamoto, Japan

  • Shinshu University Hospital, Department of Neurology

    Nagano, Japan

  • Nagasaki University Hospital, Cardiovascular Medicine

    Nagasaki, Japan

  • Okayama University Hospital_Cardiovascular Medicine

    Okayama-shi, Okayama, Japan

  • UMC Groningen afdeling Cardiologie

    Groningen, Netherlands

  • UMC Groningen

    Groningen, Netherlands

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • Hospital da Senhora da Oliveira - Guimarães

    Guimarães, Portugal

  • ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães

    Guimarães, Portugal

  • Unidade Local de Saude do Alto Ave, E.P.E.

    Guimarães, Portugal

  • ULS De Tras-Os-Montes E Alto Douro E.P.E. - Unidade Hospitalar de Vila Real

    Vila Real, Portugal

  • Hospital Universitario Puerta de Hierro Majadahonda

    Madrid, Spain

  • Hospital Universitario Puerta de Hierro Majadahonda

    Majadahonda, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.